COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS

NEWS PROVIDED BY

CollPlant

Aug 31, 2026, 08:00 ET

SHARE THIS ARTICLE

LightSolver is pioneering pure photonic computing, bringing a new computing architecture to the public markets to address the speed, energy and heat limitations of semiconductor-based computing

LightSolver has developed the world's first Laser Processing Unit™ (LPU™), combining the advantages of classical and quantum computing in a compact platform that operates without cryogenic or other extreme conditions and is designed for commercial deployment.

Commercial validation is underway with global leaders across mission-critical industries, including Boeing, a top-tier global financial institution, leading defense companies, oil and gas and energy companies, and leading engineering software organizations.

LightSolver's LPU™ is designed as a new computing layer alongside CPUs and GPUs, targeting computationally intensive workloads across scientific simulation, engineering, optimization and Physical AI.

LightSolver is advancing toward commercial availability of its LPU™ platform in 2028.

REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that it has signed a definitive agreement to acquire LightSolver Ltd. ("LightSolver"), an Israeli deep-tech company pioneering a fundamentally new computing architecture based on lasers. The acquisition is expected to close this week.

LightSolver - Illustration of future LPU Unit

CollPlant is acquiring LightSolver utilizing an equity-centric consideration structure comprising upfront closing shares, alongside pre-funded warrants and milestone-based warrants directly tied to LightSolver meeting specific technological and commercial objectives.

LightSolver has developed the Laser Processing Unit™ (LPU™), an all-optical working computing platform that uses the physical interaction of lasers to perform computation. Rather than relying exclusively on electronic transistors to execute mathematical operations and move data between processing and memory, the LPU™ maps mathematical problems onto an optical system in which large numbers of variables can interact simultaneously.

By using light itself as the computational medium, the LPU™ is designed to perform massively parallel computation with exceptional speed and energy efficiency.

LightSolver's quantum-inspired architecture captures certain advantages of physical, highly parallel computation in a room-temperature platform while avoiding many of the practical constraints associated with quantum computing.

Targeting the Most Demanding Computational Problems

LightSolver is targeting some of the world's most computationally demanding problems, using its LPU™ to accelerate large-scale linear systems, optimization and PDEs-the mathematics powering everything from robotics and Physical AI, weather prediction to plasma physics, chip design, new materials and drug discovery, and real-time mission-critical decision-making.

From Technology Validation to Commercial Deployment

LightSolver has moved beyond fundamental research into real-world validation with leading global organizations.

Boeing: LightSolver recently announced a strategic financial and engineering partnership with Boeing (NYSE:BA). This funded engagement focuses on developing and adapting LightSolver's LPU™ technology to accelerate complex physics-based aerospace simulations. Specifically, the collaboration targets degradation-driven structural effects that govern asset lifespan and maintenance planning, addressing multi-trillion-dollar lifecycle challenges by executing simulations orders of magnitude faster than traditional GPU clusters.

World leading SW Engineering tools: LightSolver is working with some of the world's leading engineering software and technology companies to bring its photonic computing technology to mission-critical simulation workloads, including advanced mechanical design, structural analysis, fluid dynamics and multiphysics simulation. These collaborations are aimed at demonstrating a new level of speed and efficiency for computationally intensive engineering and Physical AI applications.

Design Partners: Major aerospace and defense sector entities are utilizing the company's platform to solve heavy computational optimization and simulation problems.

These partnerships demonstrate the wide-ranging, high-impact commercial viability of LightSolver's technology across mission-critical sectors as it approaches full market integration.

Executive Commentary

"We are excited to announce this transformational acquisition of LightSolver, which opens an extraordinary new growth vector for CollPlant in the high-performance photonic computing and supercomputing space," said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant, "While entering the photonics market, CollPlant remains fully committed to regenerative medicine and medical aesthetics. To this end, we are actively pursuing strategic collaborations with global leaders interested in advancing, integrating, or otherwise leveraging our technology and capabilities," Mr. Tal added.

Dr. Ruti Ben Shlomi, Founder and Chief Executive Officer of LightSolver, commented, "Computing is reaching an inflection point. We believe the next great leap will come not from making transistors smaller, but from changing the very medium of computing - from electrons to light - unlocking a new era of speed and energy efficiency.

We have turned that idea from fundamental physics into a working machine. As we move toward commercial availability, our ambition is for the LPU to become a new computing layer alongside CPUs and GPUs - compressing computational workloads that can take minutes, hours or even weeks into milliseconds of LPU computation." Dr. Ben Shlomi added.

Eran Rotem, Deputy CEO and Chief Financial Officer of CollPlant stated, "This transaction marks CollPlant's entry into a market with massive growth potential, executed through a highly disciplined approach to capital allocation. Our goal is to support the continued development and commercialization of LightSolver's technology while creating a new strategic growth opportunity for CollPlant."

Highlights of Key Transaction Terms

In consideration for the acquisition of LightSolver, at or around closing, CollPlant has agreed to issue upfront ordinary shares, pre-funded warrants, milestone warrants and rollover options of CollPlant as follows:

Upfront Consideration: 3,734,476 newly issued ordinary shares of CollPlant, representing 19.7% of CollPlant's issued and outstanding share capital prior to execution of the definitive agreement.

Warrants & Milestones: Pre-funded warrants to purchase an aggregate of 6,134,363 ordinary shares of CollPlant, alongside three tranches of milestone-based warrants to purchase an aggregate of 224,078,345 ordinary shares of CollPlant, which are exercisable into CollPlant's ordinary shares upon LightSolver's achievement of specified technological and commercial milestones, with a purchase price of $0.00001 per ordinary share.

Rollover Options: Certain holders of LightSolver's options will be issued options of CollPlant to purchase an aggregate of 2,261,966 ordinary shares of CollPlant. 

Issuances of the ordinary shares of CollPlant underlying pre-funded warrants, milestone warrants and the rollover options in excess of an equity blocker designed to comply with Nasdaq Listing Rule 5635 are subject to shareholder approval.

H.C. Wainwright & Co. acted as financial advisor to CollPlant in connection with the transaction.

Rodman & Renshaw, LLC acted as financial advisor to LightSolver in connection with the transaction.

Additional details about the transaction are available in the Company's Report on Form 6-K, which has been filed with the Securities and Exchange Commission.

About LightSolver

LightSolver is an Israeli deep-tech company pioneering a new generation of high-performance computing based on the physics of light. Founded in 2020 by Weizmann Institute physicists Dr. Ruti Ben Shlomi and Dr. Chene Tradonsky, LightSolver is the developer of the Laser Processing Unit™ (LPU™), a proprietary all-optical computing architecture that uses coupled lasers to perform computation.

The LPU™ is designed to accelerate computationally intensive workloads including scientific and engineering simulation, partial differential equations, large-scale linear systems and optimization, with applications across aerospace, defense, energy, advanced engineering, financial services and Physical AI.

LightSolver is advancing its technology toward commercial deployment in collaboration with leading global organizations.

For more information about LightSolver, visit lightsolver.com.

About CollPlant

CollPlant is a pioneering technology company operating at the forefront of both regenerative medicine and advanced high-performance computing. In the healthcare sector, CollPlant is ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant-based genetic engineering technology, addressing indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

For more information about CollPlant, visit collplant.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the proposed acquisition of LightSolver by CollPlant and the expected timing of the closing thereof; the anticipated benefits, strategic rationale and growth opportunities arising from the transaction; LightSolver becoming a subsidiary of CollPlant; the future development, commercialization and market adoption of LightSolver's Laser Processing Unit™ (LPU™) technology; LightSolver's expected technological capabilities, performance, scalability and energy-efficiency advantages; the achievement of technological and commercial milestones; the expected commercial availability of LightSolver's technology and products; LightSolver's collaborations and commercial relationships; and the future prospects, business plans and growth strategies of CollPlant, LightSolver and the combined business. Forward-looking statements can be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "may," "should," "could," "might," "seek," "target," "will," "project," "continue" and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward- looking statements, including, but not limited to, the following: the ability of the parties to satisfy the conditions to closing the transaction and consummate the transaction on the anticipated timeline or at all; the risk that the anticipated benefits of the transaction are not realized, or are not realized within the expected timeframe; risks associated with integrating LightSolver's business, operations and personnel; LightSolver's ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver's technology; the ability to develop and commercialize LightSolver's products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant's ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contact Information:

CollPlant  

Eran Rotem, Deputy CEO & CFO

Email: Eran@collplant.com

+972.73.232.5600

LightSolver Ltd. 

Dr. Ruti Ben Shlomi, Founder & CEO

Email: Ruti@lightsolver.com

SOURCE CollPlant

21%

more press release views with 

Request a Demo

Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients

NEWS PROVIDED BY

Veloxis Pharmaceuticals

Aug 31, 2026, 08:00 ET

SHARE THIS ARTICLE

First participant dosed in Phase 2 RENGEVITY-201 study evaluating pegrizeprument (VEL-101) in kidney transplant recipients

Pegrizeprument is being developed as a novel maintenance immunosuppressive therapy for the prevention of organ rejection in transplant recipients

This clinical milestone reinforces Veloxis' leadership and long-standing commitment to innovation in transplantation

CARY, N.C., Aug. 31, 2026 /PRNewswire/ -- Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, today announced that the first participant has been dosed in its Phase 2 clinical trial [NCT07290777] of pegrizeprument, a novel investigational maintenance immunosuppressive agent being studied for prevention of organ rejection in kidney transplant recipients.

"Advancing pegrizeprument into a Phase 2 study is an important clinical milestone for Veloxis and brings us one step closer to offering a potential new innovative therapy in a field where opportunities for meaningful innovation remain significant. We're grateful to the participants, investigators, and study teams making this trial possible," said Carl Kraus, MD, Chief Medical Officer of Veloxis. 

The Phase 2 study, RENGEVITY-201, is a randomized, multicenter, partially blinded, active control trial evaluating the safety and efficacy of pegrizeprument compared with tacrolimus in the prevention of organ rejection in patients undergoing kidney transplantation. Up to 120 de novo kidney transplant recipients will receive rATG with corticosteroids and mycophenolate as maintenance therapy and will be randomized 1:1:1 to receive either pegrizeprument (one of two doses) or tacrolimus. The primary objectives of the study will evaluate the safety, pharmacokinetics, and pharmacodynamics of pegrizeprument. 

"Our transplant franchise is built on a commitment to advancing care for transplant recipients through both established and investigational therapies," said Stacy Wheeler, Chief Executive Officer of Veloxis. "The continued development of pegrizeprument, together with ongoing investments in transplant-focused innovation, reflects our dedication to addressing important unmet needs and expanding future therapeutic possibilities for the transplant community."

Kidney transplant recipients require life-long immunosuppression, often associated with complex dosing regimens and comorbid toxicities. Despite advancements in post-transplant clinical care, complications of immunosuppression and allograft rejection may negatively impact graft and patient survival. With an estimated 270,000 people living with a functioning kidney transplant in the United States, there remains a significant unmet need for new therapies that address these complications while maintaining adequate immunosuppression.

About pegrizeprument

Pegrizeprument is a pegylated monoclonal antibody fragment that binds to and blocks CD28‑mediated effector-T cell costimulation, without blocking CTLA-4, an important protein found on T cells that naturally helps keep the body's immune responses in check. Pegrizeprument is, therefore, expected to have a dual mechanism of action where in a direct manner, it blocks CD28‑mediated T cell activation, and indirectly, it allows for CTLA-4 mediated immunosuppressive functions. Pegrizeprument is currently being developed for the prevention of acute rejection in solid organ transplant recipients.

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to pegrizeprument for the prevention of organ rejection in patients receiving a liver transplant in December 2025 and for the prophylaxis of heart allograft rejection in patients receiving a heart transplant in March 2026.

Pegrizeprument, also known as VEL-101 and FR104, was licensed by Veloxis Pharmaceuticals, Inc. from OSE Immunotherapeutics in April 2021. As part of the license agreement, Veloxis Pharmaceuticals, Inc. obtained worldwide rights to develop, manufacture, and commercialize pegrizeprument for all transplant indications.

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a global specialty pharmaceutical company committed to improving the lives of transplant and other immunocompromised patients. Headquartered in Cary, North Carolina, USA, Veloxis is focused on the global development and commercialization of treatments that address areas of unmet needs in transplant medicine and serious infectious diseases. For further information, please visit Veloxis.com.

About Asahi Kasei

Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world's challenges across its three business sectors: Healthcare, Homes, and Material. For more information, visit https://www.asahi-kasei.com/.

Contact:

Veloxis Pharmaceuticals 

Anna Michaels

Director, Corporate Communications

media@veloxis.com

Media 

David Rosen

Argot Partners

David.rosen@argotpartners.com

646-461-6387

SOURCE Veloxis Pharmaceuticals

21%

more press release views with 

Request a Demo

Jennmar annonce un partenariat avec la mine de Kemi d'Outokumpu USA - Français

NEWS PROVIDED BY

JENNMAR

Aug 31, 2026, 08:00 ET

SHARE THIS ARTICLE

Un contrat exclusif avec la plus grande mine souterraine de Finlande renforce considérablement la présence de Jennmar en Europe

Création de Jennmar Finlande pour fournir un accompagnement local

PITTSBURGH, 31 août 2026 /PRNewswire/ -- Jennmar, fournisseur mondial de produits d'infrastructure et de services spécialisés destinés aux secteurs du génie civil, solaire, minier et de la construction, a annoncé un partenariat à long terme avec Outokumpu Corporation, leader mondial de l'acier inoxydable durable, en vue de fournir des produits de soutènement à la mine de Kemi, la plus grande mine souterraine de Finlande et la seule mine de chrome en exploitation en Europe. Dans le cadre de ce partenariat, Jennmar a créé Jennmar Finland, une nouvelle entité dont le rôle sera de rendre les transactions commerciales plus efficaces et plus fluides pour Outokumpu et les équipes dirigeantes de la mine.

Ce partenariat marque une étape commerciale importante pour Jennmar, qui renforce ainsi sa présence en Europe et sa collaboration avec les principaux opérateurs miniers mondiaux. Dans le cadre de cet accord pluriannuel, Jennmar va fournir une gamme complète d'équipements de soutien au sol essentiels à l'exploitation, notamment des ancrages de toit, des ancrages à câble, des treillis, des accessoires en acier et des résines injectables, adaptés aux conditions souterraines spécifiques de la mine de Kemi. L'entreprise va également mettre à contribution sa chaîne d'approvisionnement mondiale et son expertise technique pour renforcer la sécurité, la stabilité et l'efficacité de la production dans l'une des exploitations de chromite les plus importantes du monde occidental.

« Je suis ravi du choix d'Outokumpu en sélectionnant Jennmar pour approvisionner la mine de Kemi au cours des cinq prochaines années », a déclaré Mike Petkovich, président de Jennmar Europe. « La mine de Kemi d'Outokumpu est l'une des exploitations minières les plus importantes et les plus impressionnantes d'Europe et nous avons une opportunité exceptionnelle de mettre en avant l'étendue de notre gamme de produits et de nos compétences techniques dans la région. » Nous avons déjà établi une solide relation de travail avec les équipes commerciales et techniques de la mine de Kemi, et nous sommes constamment impressionnés par leur expertise et leur professionnalisme. Nous sommes impatients d'offrir à la mine de Kemi d'Outokumpu un service et une assistance irréprochables tout au long de ce partenariat, grâce à la création de notre nouvelle entité, Jennmar Finland. »

« À la mine de Kemi d'Outokumpu, nous menons des opérations de consolidation des sols à grande échelle afin de garantir les normes de sécurité les plus élevées pour notre personnel tout en limitant les risques liés à la production. Nous nous réjouissons de collaborer avec Jennmar, un leader du secteur reconnu à l'échelle mondiale », a déclaré Henri Simpanen, directeur de la mine de Kemi et vice-président chez Outokumpu.

La mine d'Outokumpu Kemi est la plus grande mine souterraine de Finlande et la seule mine de chrome de l'Union européenne. Avec une capacité de traitement du minerai de 2,7 millions de tonnes par an, la mine de Kemi fournit le chrome nécessaire à la production de ferrochrome et d'acier inoxydable d'Outokumpu dans la ville voisine de Tornio. Jennmar sera un partenaire de longue date pour la gestion au sol, contribuant ainsi à la stabilité et à l'efficacité durables de cet actif souterrain d'importance stratégique. Jennmar travaillera également en étroite collaboration avec la direction et les équipes techniques souterraines de la mine de Kemi afin d'accompagner un processus structuré de gestion du changement afin d'optimiser les opérations minières.

À propos de Jennmar

Jennmar est l'un des principaux fournisseurs mondiaux de produits d'infrastructure et de services spécialisés destinés aux secteurs des infrastructures civiles, de l'énergie solaire, de l'exploitation minière et de la construction. Depuis plus de 100 ans, Jennmar s'attache à fabriquer des produits et à proposer des solutions qui contribuent à la sécurité et à la productivité des travailleurs. Pour plus d'informations, veuillez consulter www.jennmar.com. 

À propos d'Outokumpu

Outokumpu a pour ambition d'être à la pointe de l'innovation en matière de matériaux et de technologies qui façonneront l'avenir. En tant que leader mondial de l'acier inoxydable durable, Outokumpu accélère la transition écologique et joue un rôle de premier plan dans le développement de métaux et de solutions à faibles émissions de CO₂ tout au long de la chaîne de valeur de l'acier inoxydable – et au-delà.

L'activité d'Outokumpu repose sur l'économie circulaire : les produits sont fabriqués à partir de plus de 90 % de matériaux recyclés, qui sont transformés en acier inoxydable entièrement recyclable, avec une empreinte carbone inférieure de 75 % à la moyenne du secteur. Cet acier est utilisé dans diverses applications dans multiples domaines d'applications, notamment les infrastructures, l'énergie, les applications industrielles et l'électroménager. Dans le cadre de sa nouvelle stratégie EVOLVE, Outokumpu s'attache à optimiser la valeur de l'acier inoxydable durable tout en élargissant son offre dans les domaines des matériaux et alliages de pointe, du ferrochrome et des technologies innovantes. Outokumpu exploite des sites de production en Finlande, en Allemagne, en Suède, aux Pays-Bas, aux États-Unis et au Mexique ; sa mine de Kemi, en Finlande, est la seule mine de chrome de l'Union européenne. En 2025, le chiffre d'affaires d'Outokumpu s'élevait à 5,5 milliards d'euros. Outokumpu emploie environ 8 600 professionnels dans près de 30 pays ; son siège social est situé à Helsinki, en Finlande, et ses actions sont cotées au Nasdaq Helsinki. Pour en savoir plus : www.outokumpu.com 

Contacts

Jennmar

Michelle Eastly

Directrice du marketing, Jennmar

meastly@jennmar.com

Outokumpu

Service de presse d'Outokumpu

tél. +358 40 351 9840

media@outokumpu.com

21%

more press release views with 

Request a Demo

Jennmar Announces Partnership with Outokumpu's Kemi Mine

NEWS PROVIDED BY

JENNMAR

Aug 31, 2026, 08:00 ET

SHARE THIS ARTICLE

Exclusive Contract with Largest Underground Mine in Finland Significantly Expands Jennmar's European Footprint

Establishes Jennmar Finland to Provide Local Support

PITTSBURGH, Aug. 31, 2026 /PRNewswire/ -- Jennmar, a global provider of infrastructure products and specialized services to the civil, solar, mining, and construction industries, announced it has entered into a long-term partnership with Outokumpu Corporation, the global leader in sustainable stainless steel, to supply ground control products for the Kemi Mine, the largest underground mine in Finland and Europe's only operational chrome mine. As part of the partnership, Jennmar has established Jennmar Finland, a new entity that will make commercial transactions more efficient and streamlined for Outokumpu and the mine's management teams.

The partnership represents a meaningful commercial milestone for Jennmar as it expands its European presence and deepens its collaboration with leading global mining operators. Under the multi‑year agreement, Jennmar will provide a full range of mission‑critical ground support equipment, including roof bolts, cable bolts, mesh, steel accessories, and pumpable resins, tailored to the Kemi Mine's unique underground conditions. The company will also leverage its global supply chain and technical expertise to enhance safety, stability, and production efficiency across one of the western world's most important chromite operations.

"I am very pleased that Outokumpu has selected Jennmar to supply the Kemi Mine for the next five years," said Mike Petkovich, President of Jennmar Europe. "Outokumpu's Kemi Mine is one of the largest and most impressive mining operations in Europe, making it an exceptional opportunity to demonstrate the breadth of our products and technical capabilities in the region. We have already built a strong working relationship with the Kemi Mine's commercial and technical teams and have been consistently impressed by their expertise and professionalism. We look forward to providing Outokumpu's Kemi Mine with our highest level of service and support throughout the partnership, facilitated by the establishment of our new entity, Jennmar Finland."

"At Outokumpu's Kemi Mine, we carry out extensive ground support operations to ensure the highest standards of safety for our personnel while mitigating production risks. We are pleased to collaborate with Jennmar, a globally recognized industry leader," said Henri Simpanen, Head of the Kemi Mine and Vice President at Outokumpu.

The Outokumpu Kemi Mine is Finland's largest underground mine and the only chrome mine within the European Union. With an ore processing capacity of 2.7 million tons annually, Kemi Mine supplies the chrome for Outokumpu's ferrochrome and stainless steel production in the nearby town of Tornio. Jennmar will serve as a long‑term ground control partner, supporting the ongoing stability and efficiency of this strategically important underground asset. Jennmar will also work closely with Kemi Mine's management and underground technical teams to support a structured change‑management process designed to optimize mining operations.

About Jennmar

Jennmar is a leading global provider of infrastructure products and specialized services to the civil infrastructure, solar, mining, and construction industries. For over 100 years, Jennmar's focus has been on manufacturing products and providing solutions that help keep workers safe and productive. For more information, please visit www.jennmar.com. 

About Outokumpu

Outokumpu's vision is to pioneer materials and technologies that power tomorrow. As the global leader in sustainable stainless steel, Outokumpu is accelerating the green transition and leading the development of low-CO₂ metals and solutions across the stainless steel value chain – and beyond.

Outokumpu's business is based on the circular economy: the products are made from more than 90% recycled materials, which are turned into fully recyclable stainless steel with up to 75% lower carbon footprint than the industry average. This steel is utilized in various applications across society, including infrastructure, energy, industrial applications and household appliances. With Outokumpu's new EVOLVE strategy, the company focuses on maximizing value in sustainable stainless steel while expanding the offering in advanced materials & alloys, ferrochrome and innovative technologies. Outokumpu operates production sites in Finland, Germany, Sweden, the Netherlands, the United States, and Mexico whilst Outokumpu's mine in Kemi, Finland is the only chrome mine within the European Union. In 2025, Outokumpu's revenue was EUR 5.5 billion. Outokumpu employs approximately 8,600 professionals in nearly 30 countries, with headquarters in Helsinki, Finland, and shares listed on Nasdaq Helsinki. Read more: www.outokumpu.com 

Contacts

Jennmar

Michelle Eastly

Marketing Director, Jennmar

meastly@jennmar.com

Outokumpu

Outokumpu media desk

tel. +358 40 351 9840

media@outokumpu.com

21%

more press release views with 

Request a Demo

Jennmar anuncia una alianza con la mina Kemi de Outokumpu USA - español

NEWS PROVIDED BY

JENNMAR

Aug 31, 2026, 08:00 ET

SHARE THIS ARTICLE

El contrato exclusivo con la mayor mina subterránea de Finlandia amplía significativamente la presencia europea de Jennmar.

Jennmar Finland se establece para brindar apoyo local.

PITTSBURGH, 31 de agosto de 2026 /PRNewswire/ -- Jennmar, proveedor global de productos de infraestructura y servicios especializados para los sectores civil, solar, minero y de la construcción, anunció una alianza estratégica a largo plazo con Outokumpu Corporation, líder mundial en acero inoxidable sostenible, para el suministro de productos de control de terreno para la mina Kemi, la mayor mina subterránea de Finlandia y la única mina de cromo operativa de Europa. Como parte de esta alianza, Jennmar ha creado Jennmar Finland, una nueva entidad que agilizará y simplificará las transacciones comerciales para Outokumpu y los equipos directivos de la mina.

Esta alianza representa un hito comercial significativo para Jennmar, ya que expande su presencia en Europa y profundiza su colaboración con operadores mineros líderes a nivel mundial. En virtud de este acuerdo plurianual, Jennmar proporcionará una gama completa de equipos esenciales para el apoyo en tierra, incluyendo pernos de techo, pernos de cable, malla, accesorios de acero y resinas bombeables, adaptados a las condiciones subterráneas únicas de la mina Kemi. La compañía también aprovechará su cadena de suministro global y su experiencia técnica para mejorar la seguridad, la estabilidad y la eficiencia de la producción en una de las operaciones de cromita más importantes del mundo occidental.

"Me complace enormemente que Outokumpu haya elegido a Jennmar para abastecer la mina Kemi durante los próximos cinco años", declaró Mike Petkovich, presidente de Jennmar Europa. "La mina Kemi de Outokumpu es una de las operaciones mineras más grandes e impresionantes de Europa, lo que representa una oportunidad excepcional para demostrar la amplitud de nuestros productos y capacidades técnicas en la región. Ya hemos forjado una sólida relación de trabajo con los equipos comerciales y técnicos de la mina Kemi y nos ha impresionado constantemente su experiencia y profesionalidad. Esperamos brindar a la mina Kemi de Outokumpu nuestro más alto nivel de servicio y apoyo durante toda la colaboración, facilitada por la creación de nuestra nueva entidad, Jennmar Finlandia".

"En la mina Kemi de Outokumpu, llevamos a cabo extensas operaciones de apoyo en tierra para garantizar los más altos estándares de seguridad para nuestro personal, a la vez que mitigamos los riesgos de producción. Nos complace colaborar con Jennmar, un líder del sector reconocido a nivel mundial", declaró Henri Simpanen, director de la mina Kemi y vicepresidente de Outokumpu.

La mina Kemi de Outokumpu es la mayor mina subterránea de Finlandia y la única mina de cromo en la Unión Europea. Con una capacidad de procesamiento de mineral de 2,7 millones de toneladas anuales, la mina Kemi suministra el cromo para la producción de ferrocromo y acero inoxidable de Outokumpu en la cercana ciudad de Tornio. Jennmar será un socio estratégico a largo plazo para el control de terrenos, garantizando la estabilidad y eficiencia de este activo subterráneo de importancia estratégica. Asimismo, Jennmar colaborará estrechamente con la dirección y los equipos técnicos subterráneos de la mina Kemi para apoyar un proceso estructurado de gestión del cambio, diseñado para optimizar las operaciones mineras.

Acerca de Jennmar

Jennmar es un proveedor líder mundial de productos de infraestructura y servicios especializados para los sectores de infraestructura civil, energía solar, minería y construcción. Durante más de 100 años, Jennmar se ha centrado en la fabricación de productos y en ofrecer soluciones que contribuyen a la seguridad y productividad de los trabajadores. Para más información, visite www.jennmar.com.

Acerca de Outokumpu

La visión de Outokumpu es ser pionera en materiales y tecnologías que impulsen el futuro. Como líder mundial en acero inoxidable sostenible, Outokumpu acelera la transición ecológica y lidera el desarrollo de metales y soluciones con bajas emisiones de CO₂ en toda la cadena de valor del acero inoxidable, y más allá.

El modelo de negocio de Outokumpu se basa en la economía circular: sus productos se fabrican con más del 90 % de materiales reciclados, que se transforman en acero inoxidable totalmente reciclable con una huella de carbono hasta un 75 % menor que la media del sector. Este acero se utiliza en diversas aplicaciones, como infraestructuras, energía, aplicaciones industriales y electrodomésticos. Con su nueva estrategia EVOLVE, Outokumpu se centra en maximizar el valor del acero inoxidable sostenible, ampliando su oferta en materiales y aleaciones avanzadas, ferrocromo y tecnologías innovadoras. Outokumpu cuenta con plantas de producción en Finlandia, Alemania, Suecia, Países Bajos, Estados Unidos y México, y su mina de Kemi, Finlandia, es la única mina de cromo de la Unión Europea. En 2025, los ingresos de Outokumpu ascendieron a 5.500 millones de euros. Outokumpu emplea a aproximadamente 8.600 profesionales en casi 30 países, con sede en Helsinki, Finlandia, y cotiza en el Nasdaq Helsinki. Más información: www.outokumpu.com 

Contactos

Jennmar

Michelle Eastly

Directora de Marketing, Jennmar

meastly@jennmar.com

Outokumpu

Outokumpu media desk

Tel. +358 40 351 9840

media@outokumpu.com

21%

more press release views with 

Request a Demo

Zillow is helping 78,000 renters and counting turn monthly bills into credit progress

NEWS PROVIDED BY

Zillow

Aug 31, 2026, 08:00 ET

SHARE THIS ARTICLE

Zillow has reported nearly 2 million on-time rent payments to credit bureaus for free since launching its rent reporting program in 2024

In July, more than 78,000 renters who paid on time through Zillow had their payments reported to credit bureaus. That's 26% more than a year ago, reflecting strong demand for tools that translate rent into credit history.

Insufficient credit history was responsible for nearly one-third of mortgage application denials in 2025, edging debt-to-income ratio as the most common reason cited.

Nearly 4 million U.S. renters could become eligible for a mortgage by having their on-time rent payments reflected in their credit history, per VantageScore.

SEATTLE, Aug. 31, 2026 /PRNewswire/ -- Nearly one-third of mortgage applicants are denied a loan because of insufficient credit history, making it the most common reason for a denial.1 Yet the average renter's biggest monthly expense doesn't count toward their credit score. Zillow® is helping to change that. Since launching rent reporting in 2024, Zillow has reported more than 1.78 million on-time rent payments to credit bureaus for free.

More than one-third of renters planning a near-term move say they plan to buy their next home, but the credit barrier too often stands in the way. Zillow's rent reporting programs let renters build credit history with payments they're already making. Those who pay their rent on Zillow can choose to have those on-time payments reported to major credit bureaus for free.

Zillow is continuing to help a growing number of renters build their credit history via this program. More than 78,000 renters had payments reported in July, the most in any single month since the program launched, and up 26% from a year ago.

"Affordability is the headline in housing right now, and access to financing is a very important part of the story," said Michael Sherman, general manager and senior vice president of Zillow Rentals®. "Credit history is a barrier standing in the way of too many potential buyers. Rent reporting is a direct way to address that."

Rent reporting could move millions of renters closer to a mortgage. A report by VantageScore found that nearly 4 million homebuying age renters could become eligible for a mortgage — reaching a VantageScore 4.0 of 620 or higher — when on-time rent payments are reflected in their credit history.

In November 2025, Zillow expanded its rent reporting program to all renters via its CreditClimb tool, powered by Esusu. This additional offering means that every renter — even those who do not pay on Zillow — can now have their on-time rent payments reported to credit bureaus. Renters who consistently report their payments in Esusu-powered programs like CreditClimb have seen an average credit score increase of 53 points.

"Every on-time rent payment is evidence of the financial responsibility lenders want to see. We are giving renters ways to get credit for what they are already doing every month," Sherman said. "These programs are part of how Zillow supports people wherever they are, from finding a rental, to building credit, to eventually connecting them with a great agent or loan officer when they are ready to buy."

For renters ready to take the next step, Zillow offers tools to help them understand what they can afford and find available assistance. BuyAbility℠ gives buyers a personalized estimate of what they can afford based on their finances and current mortgage rates. Zillow for-sale listings also include down payment assistance programs buyers may qualify for in their area, helping address another common barrier to homeownership.

About Zillow Group

Zillow Group, Inc. (Nasdaq: Z and ZG) is reimagining real estate to make home a reality for more and more people.

As the most visited real estate app and website in the United States, Zillow connects hundreds of millions of consumers with innovative technology, trusted agents and loan officers, and seamless digital solutions. With industry-leading tools and resources, Zillow supercharges real estate professionals so they can grow their businesses and deliver exceptional client experiences. For renters and housing providers, Zillow offers not only a robust marketplace but a set of end-to-end products and services to streamline applications, leases, payments and more.

Zillow's ecosystem spans the entire home journey — from dreaming and shopping to renting, buying, selling and financing.

Zillow Group's affiliates, subsidiaries and brands include Zillow®, Zillow Premier Agent®, Zillow Home Loans®, Zillow Rentals®, Zillow® New Construction, Trulia®, StreetEasy®, Out East®, HotPads®, Follow Up Boss®, ShowingTime®, dotloop® and Zillow® Closing.

All marks herein are owned by MFTB Holdco, Inc., a Zillow affiliate. Zillow Home Loans, LLC is an Equal Housing Lender, NMLS #10287 (www.nmlsconsumeraccess.org). © 2026 MFTB Holdco, Inc., a Zillow affiliate.

(ZFIN)

_____________________________

1 Source: Zillow analysis of 2025 Home Mortgage Disclosure Act data. Credit history was cited for 32.88% of mortgage denials for primary home purchases with conventional loans. That is the highest of any factor. Debt-to-income ratio was cited for 32.86% of denials for primary home purchases with conventional loans.

SOURCE Zillow

21%

more press release views with 

Request a Demo

SIBIONICS presenta GS3 en Melbourne, impulsando un monitoreo de glucosa en sangre más eficiente basado en IA USA - español

NEWS PROVIDED BY

SIBIONICS

Aug 31, 2026, 07:57 ET

SHARE THIS ARTICLE

MELBOURNE, Australia, 31 de agosto de 2026 /PRNewswire/ -- SIBIONICS presentó su innovadora tecnología de sensores y monitoreo de la glucosa en sangre mediante inteligencia artificial en el congreso conjunto IDF-WPR, ADC y Metabolic Diseases 2026, celebrado en Melbourne del 18 al 21 de agosto. A través del stand n.º 1, un simposio científico y entrevistas in situ con educadores acreditados en diabetes (CDE), la empresa reunió tecnología avanzada, evidencia clínica y perspectivas del mundo real.

At IDF-WPR 2026 & ADC 2026 & Metabolic Diseases 2026, we shared how GS3 is bringing AI into everyday glucose management — from easier meal logging and food analysis to smarter insights into glucose trends.

La historia tecnológica detrás de GS3 va mucho más allá del monitoreo de la glucosa en sangre. El trabajo de SIBIONICS en interfaces cerebro-computadora incluye una prótesis retiniana diseñada para proporcionar percepción visual limitada a personas con pérdida profunda de la visión causada por enfermedades degenerativas de la retina externa, como la retinosis pigmentaria. Estos sistemas de alta complejidad requieren biosensores precisos y estables, así como un procesamiento de señales robusto. SIBIONICS ha transformado esta ingeniería de alto nivel en una tecnología médica más accesible: el monitoreo continuo de la glucosa en sangre (CGM). Esta misma plataforma ahora es compatible con GS3, un sensor de CGM de 14 días calibrado de fábrica con un perfil de 2,9 mm, diseñado para proporcionar una monitorización fiable con una mínima incomodidad en el cuerpo.

En el simposio "Más allá de la glucosa: el futuro integrado de CGM, CKM e IA en la diabetes", organizado conjuntamente por SIBIONICS y Air Liquide Healthcare, el presidente de la sesión, el profesor Sofianos Andrikopoulos, consejero delegado del grupo de la Sociedad Australiana de Diabetes, reunió tres perspectivas. El profesor David O'Neal, de la Universidad de Melbourne y subdirector del Centro Australiano para la Aceleración de las Innovaciones en Diabetes, revisó la evidencia clínica emergente sobre el monitoreo continuo de glucosa en sangre y monitoreo de cuerpos cetónicos. La profesora asociada Shannon Lin, especialista en diabetes y nutrición de la Universidad Tecnológica de Sídney, examinó cómo el CGM puede ir más allá de la simple visualización de datos hacia un apoyo personalizado, predictivo y práctico. El profesor Wei Qiang, médico jefe asociado y subdirector de Endocrinología y Metabolismo del Primer Hospital Afiliado de la Universidad Xi'an Jiaotong, describió un ecosistema integrado impulsado por IA que conecta la detección confiable, el contexto y el aprendizaje.

Durante todo el congreso, médicos y educadores en diabetes visitaron el stand de SIBIONICS para conocer el GS3 y analizar sus capacidades para la gestión de la glucosa en sangre. En entrevistas anónimas, los educadores en diabetes describieron el sensor como pequeño, ligero, cómodo y fácil de configurar. Destacaron el potencial de la detección de picos de glucosa asistida por IA, el registro simplificado de comidas y el análisis de alimentos que relaciona las tendencias de glucosa con el contexto de las comidas. Sus comentarios también subrayaron la importancia de la personalización, las estimaciones claras de carbohidratos y los cronogramas de eventos clínicamente útiles, reforzando la idea de que la IA debe complementar la educación y el apoyo a la toma de decisiones, no reemplazar la atención profesional.

De cara al futuro, SIBIONICS planea integrar su plataforma de sensores con el monitoreo continuo de cuerpos cetónicos, la administración de insulina, la inteligencia artificial y otras tecnologías para la diabetes. El objetivo es crear un ecosistema más completo, fiable y eficiente que acelere el proceso desde la obtención de datos hasta la comprensión, y desde la comprensión hasta la acción.

21%

more press release views with 

Request a Demo

SWI se convierte en socio de NVIDIA Cloud (NCP) USA - español

NEWS PROVIDED BY

SWI Group

Aug 31, 2026, 07:58 ET

SHARE THIS ARTICLE

ÁMSTERDAM, 31 de agosto de 2026 /PRNewswire/ -- SWI Group (AMS: SWICH), una empresa de inversión con una capacidad de generación de energía de 3,6 gigavatios en Europa y Estados Unidos, ha anunciado que se ha convertido en miembro del programa NVIDIA Cloud Partner (NCP) como socio preferente.

SWI Group se une a un selecto grupo de socios de NVIDIA con competencias validadas y experiencia demostrada en infraestructura de IA. La membresía en la Red de Socios de NVIDIA le brinda a SWI Group acceso a arquitecturas de referencia y configuraciones validadas de NVIDIA, lo que facilita el despliegue de nueva capacidad certificada por NVIDIA a medida que la plataforma se expande.

Como socio preferente, SWI Group puede implementar infraestructura de computación acelerada por NVIDIA en una amplia gama de cargas de trabajo de IA, desde el entrenamiento y ajuste de modelos hasta la inferencia a escala de producción y la IA automatizada. Las competencias de SWI, certificadas por NVIDIA, abarcan computación, redes y software empresarial. En conjunto, reflejan la ambición de la compañía de operar como un proveedor de computación integrado verticalmente: implementando las últimas GPU de NVIDIA en sus propias fábricas de IA y ejecutando una plataforma de IA en la nube con el software NVIDIA AI Enterprise.

"SWI Group da un paso más en su camino para convertirse en un actor global de IA totalmente integrado verticalmente: primero fueron los terrenos, la energía y la infraestructura; ahora los chips, los tokens y las aplicaciones. Nuestra colaboración con NVIDIA nos ayudará a consolidar una posición sólida en Europa, Estados Unidos y otros mercados", declaró Max-Hervé George, fundador y consejero delegado de SWI Group.

SWI también adquirió recientemente una participación mayoritaria en Genesis Digital Assets (ahora conocida como SWI Digital), una empresa de centros de datos de 1,3 gigavatios, lo que representa su principal presencia en Estados Unidos. En Europa, SWI ha construido AiOnX, una cartera de 2,3 gigavatios en Irlanda, Reino Unido, España, Dinamarca e Italia, y uno de sus centros ha sido arrendado a un proveedor de servicios en la nube a gran escala.

La inversión en otras áreas del negocio del Grupo SWI continuará, y recientemente se anunció que Varia US, gestionada por SWI, ha firmado un acuerdo de empresa conjunta por valor de 693,9 millones de dólares con Brookfield Asset Management.

Acerca de SWI Group

SWI Group (SWI Capital Holding Ltd) es un grupo de inversión global especializado en mercados privados, que cotiza en Euronext Amsterdam con el símbolo SWICH. Fruto de la fusión de Icona y Stoneweg, el Grupo invierte su propio capital en infraestructura digital, bienes raíces y otras oportunidades en el mercado privado, combinando un enfoque emprendedor con la disciplina institucional. Para más información, visite www.swi.com.

21%

more press release views with 

Request a Demo

Defense Metals Resource Upgrade Drilling Intersects 2.86% TREO over 65 Metres; Including 6.15% TREO over 20 Metres at the Wicheeda Rare Earth Project

NEWS PROVIDED BY

Defense Metals Corp.

Aug 31, 2026, 07:00 ET

SHARE THIS ARTICLE

VANCOUVER, BC, Aug. 31, 2026 /PRNewswire/ -- Defense Metals Corp. ("Defense Metals" or the "Company"); (TSXV: DEFN) (OTCQB: DFMTF) (FSE:35D) is pleased to announce assay results for an initial eleven core drill holes, totalling 1,633 metres (m), completed during spring 2026 at its 100% owned Wicheeda Rare Earth Project (the "Wicheeda Project") located near Prince George, Canada.

Figure 1. Wicheeda Drill Holes WI26-95 & WI26-96 - Cross Section Looking Northeast

Figure 2. Wicheeda Drill Holes WI26-99 & WI26-100 - Cross Section Looking Northeast

Figure 3. Wicheeda Drill Holes WI26-102 & WI26-103 - Cross Section Looking Northeast

Robin Jones, Defense Metals VP Projects, commented: "We're exceptionally pleased that all eleven drill holes reported in today's news release intersected significant widths of high to moderate grade Rare Earth Element mineralization within the pit confines defined by the 2025 Preliminary Feasibility Study and are expected to contribute positively to a resource classification uplift."

Highlights of this season's drill program include:

Resource infill drill hole WI26-96 was collared in sedimentary rocks and drilled towards the Wicheeda Deposit. This hole intersected REE mineralized mixed xenolithic dolomite carbonatite rock that returned assays of 2.86% Total Rare Earth Oxide ("TREO") over 65 m; including a higher-grade interval averaging 6.15 % TREO over 20.3 metres (see Table 1 and Figure 1).

Collared from the same setup, drill hole WI26-93, cutting obliquely across the southern margin of the Wicheeda Deposit, yielded a broad intersection of mixed xenolithic and dolomite carbonatite grading 1.70% TREO over a 184 m interval; including 2.52% TREO over 57 m.

Drill holes WI26-100 and WI26-102, collared 100 m to the northwest of WI26-93, were oriented southwest and southeast, respectively, drilling outward from inside the Wicheeda Deposit. WI26-100 collared into REE mineralized dolomite carbonatite averaged, from surface, 2.40% TREO over 85 m; within a broader mineralized zone returning 1.55% TREO over 149 m. Drill hole WI26-102 also collared into REE mineralized dolomite carbonate yielded a higher-grade intercept returning 3.25% TREO over 34.3 m, within a broader interval averaging 2.62% TREO over 73.4 m to a depth of 79 m downhole with TREO assays for the remaining 47 m still pending. 

Table 1. Wicheeda REE Deposit 2026 Diamond Drill Intercepts1

Hole ID

From 

(m)

To 

(m)

Interval 

(m)

TREO2 

(%)

Ce2O3 

(%)

La2O3 

(%)

Nd2O3 

(%)

Pr2O3 

(%)

Sm2O3 

(ppm)

Gd2O3 

(ppm)

Eu2O3 

(ppm)

Dy2O3 

(ppm)

Tb4O7 

(ppm)

Ho2O3 

(ppm)

WI26-86

(225/-60)

1.0

70.8

69.8

3.69

1.81

1.26

0.40

0.15

382

169

79

38

14

4

including 

3.0

35.0

32.0

5.03

2.46

1.74

0.53

0.20

479

211

102

51

18

5

WI26-93

(275/-45)

91.6

276.0

184.4

1.70

0.83

0.52

0.22

0.07

274

137

60

41

12

5

including 

96.4

153.1

56.7

2.52

1.23

0.73

0.36

0.11

456

224

102

76

22

10

WI26-94

(284/-60)

77.1

135.0

57.9

0.82

0.41

0.23

0.11

0.04

159

93

38

42

10

6

WI26-95

(320/-45)

64.0

100.0

36.0

2.42

1.18

0.78

0.30

0.10

350

166

66

44

14

5

WI26-96

(320/-60)

60.9

126.0

65.1

2.86

1.39

0.84

0.40

0.13

519

252

109

80

24

10

including 

93.0

113.3

20.3

6.15

2.98

1.78

0.89

0.29

1138

530

236

146

48

17

WI26-97

(110/-70)

2.9

119.0

116.2

1.96

0.95

0.63

0.24

0.08

292

144

67

38

13

4

WI26-98

(120/-45)

3.1

122.0

119.0

1.55

0.76

0.49

0.19

0.06

213

110

47

39

11

5

including 

3.1

56.0

53.0

2.34

1.14

0.79

0.27

0.09

282

130

58

34

12

4

WI26-99

(140/-45)

3.4

115.0

111.6

1.63

0.79

0.52

0.20

0.07

242

131

50

45

12

6

including

3.4

61.0

57.6

2.65

1.29

0.88

0.31

0.11

354

174

67

47

14

5

WI26-100

(140/-60)

2.3

151.0

148.7

1.55

0.76

0.49

0.19

0.06

226

109

48

32

10

4

including 

2.3

86.9

84.6

2.40

1.16

0.79

0.29

0.10

328

152

67

37

13

4

WI26-101

(170/-60)

2.3

111.0

108.8

1.99

0.98

0.64

0.24

0.08

273

135

58

42

13

5

including 

2.3

88.0

85.8

2.40

1.18

0.78

0.28

0.10

310

146

64

39

13

5

WI26-102

(200/-45)

5.7

79.1

73.4

2.62

1.28

0.86

0.31

0.11

343

162

71

41

14

4

including 

5.7

40.0

34.3

3.25

1.58

1.10

0.36

0.13

390

187

82

51

16

6

_______________________________

1The true width of REE mineralization is estimated to be 70-100% of the drilled interval.

2TREO % sum of CeO2, La2O3, Nd2O3, Pr6O11, Sm2O3, Eu2O3, Gd2O3, Tb4O7, Dy2O3 and Ho2O3.

The 2026 Wicheeda Project drill program comprised 31 core drill holes totalling 5,345 m inclusive of:

20 holes (3,136 m) of resource upgrade and infill drilling

7 holes (1,507 m) pit slope geotechnical drilling

4 holes (702 m) waste rock geochemical drilling

The resource infill drilling was designed to upgrade a significant tonnage of inferred resources, constrained within the limits of the current Wicheeda Project Preliminary-Feasibility Study ("PFS") ultimate pit design, to an indicated or better category (see Defense Metals news release dated February 18, 2025).

This news release presents Rare Earth Element ("REE") assay results for the first of 10-resource upgrade and infill, and one pit slope geotechnical drill hole (WI26-86) targeting the southern pit perimeter of the Wicheeda Deposit.

Analysis of the remaining 10 resource upgrade and infill drill holes is currently underway at ALS Canada Ltd. ("ALS") laboratories in Vancouver, Canada and are expected to be released in the coming weeks.

Methodology and Quality Assurance/Quality Control

The analytical work reported on herein was performed by ALS Canada Ltd. ("ALS") at their Langley (sample preparation) and Vancouver (ICP-MS fusion), B.C. facilities. ALS is an ISO-IEC 17025:2017 and ISO 9001:2015 accredited geoanalytical laboratory and is independent of the Defense Metals and the Qualified Person ("QP"). Drill core samples were subject to crushing at a minimum of 70% passing 2 mm, followed by pulverizing of a 250-gram split to 85% passing 75 microns. A 0.1-gram sample pulp was then subject to multi-element ICP-MS analysis via lithium-borate fusion to determine individual REE content (ME-MS81h). Defense Metals follows industry standard procedures for the work carried out on the Wicheeda Project, with a quality assurance/quality control ("QA/QC") program. Blank, duplicate, and standard samples were inserted into the sample sequence sent to the laboratory for analysis. The QP and Defense Metals detected no significant QA/QC issues during review of the data.

Qualified Person

The scientific and technical information contained in this news release as it relates to the Wicheeda Project has been reviewed and approved by Kristopher J. Raffle, P.Geo. (B.C.), Principal and Consultant of APEX Geoscience Ltd. of Edmonton, Alberta, and a consultant to the Company, who is a "Qualified Person" as defined in NI 43-101

About Defense Metals Corp. and the Wicheeda Rare Earth Element Project

Defense Metals Corp. is an advanced rare earth elements ("REE") development company focused on delivering strategically critical metals to the western world defence, high-technology, and clean energy supply chains. The Company's primary asset is its 100%-owned Wicheeda REE deposit, located near Prince George, British Columbia, Canada.

The Wicheeda Project is one of the most advanced, undeveloped REE deposits in North America or Europe, featuring a robust mineral resource and mining reserve, as detailed in the Company's 2025 Preliminary Feasibility Study ("PFS"; refer to Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects. The PFS shows the economic potential of the deposit and supports future project development.

Defense Metals is committed to advancing the Wicheeda Project through the Feasibility Study stage, permitting, and ultimately into production, positioning the Company to become a reliable supplier of critical REEs that are essential to modern defence systems, advanced manufacturing, and energy-efficient technologies.

The PFS for the Wicheeda Rare Earth Element Project is preliminary in nature and includes numerous assumptions regarding metallurgy, capital and operating costs, and market conditions.

Mineral reserves and the economic outcomes, as projected in the PFS, are subject to significant uncertainties, and there is no certainty that the results of the PFS will be realized. Additional studies, including a Feasibility Study, and permitting, are required before a production decision can be made for the Wicheeda Project.

For further information, please visit www.defensemetals.com or contact:

Ali Mahdavi

SVP Corporate Development

Email: am@spinnakercmi.com

+1.416.962.3300

Mark Tory

President and CEO

Email: mark@defensemetals.com 

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding "Forward-Looking" Information

This news release contains "forward‐looking information or statements" within the meaning of applicable securities laws, which may include, without limitation, any statements (expressed or implied) relating to advancing the Wicheeda Project. Forward-looking statements are typically identified by words such as "plan," "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. All statements in this news release, other than statements of historical facts, that address events, contribution or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of rare earth elements, the anticipated costs and expenditures, the ability to achieve its goals, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company's views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties relating to the interpretation of exploration and metallurgical results, risks related to the inherent uncertainty of exploration and development and cost estimates, the potential for unexpected costs and expenses and those other risks filed under the Company's profile on SEDAR+ (www.sedarplus.ca). While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, adverse weather and climate conditions, failure to maintain or obtain all necessary government permits, approvals and authorizations, failure to maintain or obtain community acceptance (including First Nations), risks relating to unanticipated operational difficulties (including failure of equipment or processes to operate in accordance with specifications or expectations, cost escalation, unavailability of personnel, materials and equipment, government action or delays in the receipt of government approvals, industrial disturbances or other job action, and unanticipated events related to health, safety and environmental matters), risks relating to inaccurate geological, metallurgical, engineering and pricing assumptions, decrease in the price of rare earth elements, the impact of viruses and diseases on the Company's ability to operate, restriction on labour and international travel and supply chains, loss of key employees, consultants, officers or directors, increase in costs, delayed results, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward–looking statements or forward–looking information, except as required by law.

SOURCE Defense Metals Corp.

21%

more press release views with 

Request a Demo

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities USA - English

NEWS PROVIDED BY

RedHill Biopharma Ltd.

Aug 31, 2026, 07:00 ET

SHARE THIS ARTICLE

Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability

--

Realizes substantial value from RedHill's 70% stake in Talicia, currently held within a shared ownership and economic structure, while immediately creating a stronger liquidity position and fully funding the next major steps in RedHill's transformational commercial expansion

--

Under the terms of the agreement, Apotex will pay RedHill an upfront payment of $18 million plus up to an additional $35 million in potential worldwide net sales milestone payments

RALEIGH, N.C. and TEL AVIV, Israel, Aug. 31, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the divestment of its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) ("Apotex") for an upfront payment of $18 million plus up to an additional $35 million in potential payments based on worldwide net sales milestones.

"This transaction is a pivotal milestone for RedHill. We are converting our 70% stake in Talicia into immediate capital, significantly stronger liquidity and meaningful potential upside, while fully funding the next major step in our commercial business expansion. I want to thank the RedHill team for developing and positioning this important product for success, targeting H. pylori infection, the main cause of gastric cancer and stomach ulcers," said Dror Ben-Asher, RedHill's Chief Executive Officer. "We are confident that given its proven capabilities, Apotex is the right home to grow Talicia globally. We thank Apotex for their partnership on the successful conclusion of this transaction, which unlocks the resources needed to scale RedHill's existing gastrointestinal (GI) commercial franchise into a stronger and larger one, including new, high-value, FDA-approved product opportunities intended to drive sustained growth and accelerate our path toward operational profitability."

Under the terms of the agreement, RedHill received $18 million in cash and has the potential to receive up to an additional $35 million in payments based on worldwide net sales milestones from Apotex. In return, Apotex will receive RedHill's 70% interest in Talicia, following Apotex's prior acquisition of Cumberland Pharmaceuticals Inc.'s U.S. branded business, which included Cumberland Pharmaceuticals Inc.'s 30% ownership in Talicia.

RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.

About RedHill Biopharma 

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), an ongoing Phase 2 study in prostate cancer in combination with darolutamide and a Phase 2/3 program for hospitalized COVID-19; (ii) RHB-102 (Bekinda®), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.

More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.

About Apotex 

Apotex is a Canadian-based global health company. Apotex improves everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, Apotex is the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of that sale; the Company's ability to acquire or develop new products, expected revenue growth, the Company's anticipated path toward operational profitability, and the Company's strategic plans for its commercial business. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the divestment of Talicia does not result in any planned asset acquisitions, or that any such acquisitions are not commercially successful; the risk that proceeds from the transaction are insufficient to fund the Company's strategic plans or that such plans do not achieve the anticipated results; the risk that opaganib is not accepted into Ebola virus disease control programs, or if accepted, that it does not demonstrate efficacy; the risk that development of RHB-204 for Crohn's disease may not be completed, or if completed may not be approved or may not achieve commercial success; the risk that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company's ability to regain and maintain compliance with Nasdaq's listing requirements, including the minimum bid price requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that the Company will not receive future milestone payments under its existing agreements, including under the Apotex agreement, or that they will be less than anticipated; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates; (v) the Company's ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (viii) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) the Company's ability to collect on its judgement against Kukbo; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 27, 2026. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Company contact:

Adi Frish

Chief Corporate & Business Development Officer

RedHill Biopharma

adi@redhillbio.com 

Category: Corporate

SOURCE RedHill Biopharma Ltd.

21%

more press release views with 

Request a Demo